Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inclacumab - Global Blood Therapeutics

Next Previous
X
Search
Drug Profile

Inclacumab - Global Blood Therapeutics

Alternative Names: DSM ACC2641; LC1004-002; PF-07940370; R 1512; RG1512; RO 4905417

Latest Information Update: 16 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab; Roche
  • Developer Global Blood Therapeutics; Roche
  • Class Anti-inflammatories; Anti-ischaemics; Cardiovascular therapies; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Sickle cell anaemia; Vaso-occlusive crisis
  • Discontinued Acute coronary syndromes; Myocardial infarction; Peripheral vascular disorders

Most Recent Events

  • 06 Jun 2024 Pfizer completes a phase III trial in Vaso-occlusive-crisis (In adolescents, In adults, In children, In the elderly) in Brazil, Colombia, Egypt, Ghana, Nigeria, Oman, Saudi Arabia, Tanzania, Turkey, the UK, Zambia, US, Lebanon, France, Germany and Italy (IV) (NCT04935879)
  • 24 Nov 2023 Pfizer terminates a phase III trial in Vaso-occlusive-crisis (In adolescents, In children, In the elderly, In adults) in USA, Italy, Kenya, Lebanon, Oman, Turkey, Germany, Italy, Brazil, Colombia, France, Nigeria, Saudi Arabia, United Kingdom, Zambia (IV), due to poor accrual and associated recruitment challenges (NCT04927247) (EudraCT2020-005287-60)
  • 05 Oct 2022 Global Blood Therapeutics has been acquired by Pfizer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top